Explore Supplements Subscribe
The VerdictMODERATE CONVICTIONWorth-It: Low ROI (52/100)

"Adaptogen" is a 1947 word for a category that mostly doesn't exist — specific plants help specific people for specific things.

Open the cabinet. If you own a multi-adaptogen "stress blend," check the per-plant dose. If any single plant is below its trial dose (ashwagandha 300 mg, rhodiola 200 mg, ginseng 200 mg), you are paying for marketing, not biology.

  1. Standardised ashwagandha (KSM-66 or Sensoril, 300–600 mg/d, about one capsule to two capsules) reliably reduces stress and anxiety in already-stressed adults. It does not turn unstressed adults into Zen monks.
  2. There is no "adaptogen pathway." Each canonical plant has its own active ingredient, its own endpoint, and its own population. The category is a marketing wrapper.
  3. Multi-adaptogen "stress blends" of five herbs in one capsule have zero published trials showing they beat any single plant alone. Buy one standardised single-plant extract instead.

That's the general answer. Your stack is different.

Check your whole stack
SH
Dr. Seth Holbrook, DPT — Doctor of Physical Therapy • Coach to 300+ clients
I built The Verdict to cut through recycled health advice and show what the evidence actually supports.

Herbal · Adaptogen · Category Synthesis

Adaptogens — What's Real, What's Marketing

A 1947 Soviet pharmacology label became a billion-dollar shelf. Here's what the evidence actually supports.

Conditional

SCROLL ↓

Open your supplement cabinet. If you own a multi-adaptogen "stress blend," check the per-plant dose on the label — if any single plant is below its trial dose (ashwagandha 300 mg, rhodiola 200 mg, ginseng 200 mg), you are paying for marketing.

No published RCT shows a five-herb blend beats the best single plant for the same endpoint. The blend is the marketing concept; the standardised single-plant extract is the biology.

Takes less than 2 minutes. Cabinet only.

The Verdict

"Adaptogen" is a 1947 word for a category that mostly doesn't exist — specific plants help specific people for specific things.

"Adaptogen" sounds like one ingredient. It is actually a 1947 Soviet pharmacology label that got pasted onto a dozen different plants — ashwagandha (an Indian root), rhodiola (an Arctic flower), ginseng (a Korean root), maca (a Peruvian tuber), reishi (a Chinese mushroom). Each plant has its own active chemistry and its own narrow effect — like calling a hammer, a screwdriver, and a saw all "tools" and then selling you a bag of five "tools" for stress. You wanted the right tool, not five.

  1. The verdictStandardised ashwagandha (KSM-66 or Sensoril, 300–600 mg per day, about one to two capsules) reliably reduces stress and anxiety in already-stressed adults — but does very little in people who are not stressed to begin with.
  2. What most people get wrongThere is no "adaptogen pathway" your body uses. Each canonical plant has its own active compound, its own endpoint, and its own population. Buying a five-herb "stress blend" is buying a marketing concept; no published trial shows the blend beats the best single plant alone.
  3. The protocol in plain EnglishPick the plant by the goal. Stress: ashwagandha 300–600 mg/d (one or two capsules of a standardised KSM-66 or Sensoril extract). Acute mental fatigue: rhodiola SHR-5 200–400 mg/d in the morning. Cognitive load: Panax ginseng G115 200–400 mg/d. Menopausal symptoms: gelatinised maca 1,500–3,000 mg/d (about half a teaspoon to a full teaspoon).

Best for

Documentably stressed adults (ashwagandha), students or workers under acute cognitive load (rhodiola), peri/postmenopausal women (gelatinised maca), stressed adults seeking a cognitive edge (Panax ginseng).

Skip if

Healthy and unstressed and using the supplement for "energy"; pregnant or lactating; on thyroid hormone, immunosuppressants, MAOIs, or warfarin; autoimmune disease; or buying a five-herb blend expecting category synergy.

Want the full evidence? Keep scrolling

The Protocol

Adaptogen protocol visualization

There is no category-wide dose. Each plant has its own pharmacology and its own studied range. The table below uses the form, dose, and duration that match the published RCT evidence. Trial-ceiling doses act as practical upper bounds — no regulatory body has set tolerable upper intake levels for any adaptogen.

Dosing by plant and population

Plant Population Dose Form Timing
Ashwagandha Stressed adults 300–600 mg/d KSM-66 or Sensoril standardised root Once or twice daily, with food
Rhodiola rosea Acute mental fatigue 200–400 mg/d SHR-5 (3% rosavins, 1% salidroside) Morning, single dose
Panax ginseng Stressed adults seeking cognitive edge 200–400 mg/d G115 or equivalent ginsenoside-standardised Morning
Maca Peri / postmenopausal women 1,500–3,000 mg/d (about half to one teaspoon) Gelatinised only — not raw Daily, with food
Ashwagandha (strength) Recreationally trained men + resistance training 600 mg/d (300 mg twice daily) KSM-66 standardised root BID, with food
Any adaptogen Healthy unstressed adults No reproducible RCT signal in this population — —

Forms — what to actually buy

KSM-66 ashwagandha

Standardised root extract

The single most-studied standardised adaptogen extract. Stress, anxiety, cortisol modulation in already-stressed adults.

~£15–30 / month at 600 mg/d

Sensoril ashwagandha

Root + leaf, higher withanolide %

Higher concentration per mg, but leaf adds compounds with a different safety profile. Stress, sleep.

~£15–30 / month

Whole ashwagandha root powder

Non-standardised

Lower bioactive yield per gram. Capsule doses rarely match the standardised-extract trials. Usable in larger spoonfuls in traditional preparations only.

~£5–10 / month

Rhodiola SHR-5

3% rosavins, 1% salidroside

The standardised extract used in nearly all positive rhodiola trials. Acute mental fatigue, single-dose cognitive demand.

~£15–25 / month

Non-standardised rhodiola

Wild rosavin / salidroside variation

Many products on shelves are Rhodiola crenulata (a different species), not Rhodiola rosea. Adulteration is widespread. Not recommended.

~£5–15 / month

Panax ginseng G115

Ginsenoside-standardised

Cognitive performance under stress. Individual response varies because gut bacteria convert ginsenosides to the active metabolite.

~£15–30 / month

Maca, gelatinised

Heat-pressure processed root

Menopausal symptoms and libido (via an endocannabinoid pathway, not testosterone). Raw maca is not the form used in clinical trials.

~£10–20 / month

Multi-adaptogen "stress blends"

5+ plants, often under-dosed each

No published RCT shows a blend beats the best single plant for the same endpoint. Skip — buy a single standardised extract instead.

~£25–45 / month

Absorption tips

Ashwagandha withanolides are fat-soluble — take with a meal containing some fat. Rhodiola is studied empty-stomach in most trials; evening dosing causes jitteriness and disrupts sleep, so morning dosing is the default. Panax ginseng's active metabolites are produced by gut bacteria, which is why individual response varies. Maca needs to be gelatinised (a heat-pressure step that reduces glucosinolates and improves digestibility) — raw maca powder is not the form used in trials.

Safety & Interactions

Safety and interactions visualization

"It's just a herb" is not a safety argument. Adaptogens have real drug interactions and several rare-but-serious safety signals. The interactions below cluster around the medications that change how stress hormones, immune function, blood clotting, and thyroid function behave.

Drug interactions

Ashwagandha + levothyroxine (thyroid hormone) — Moderate

May raise T4/T3 levels. Risk of iatrogenic hyperthyroidism in treated patients. Avoid or monitor TSH closely if initiating.

Ashwagandha + immunosuppressants (cyclosporine, tacrolimus) — Moderate to high (theoretical)

Theoretical antagonism via immunomodulation. Avoid in transplant patients.

Ashwagandha + sedatives, benzodiazepines, alcohol — Moderate

Additive central nervous system depression. Avoid combination.

Rhodiola + warfarin and CYP3A4 substrates — Moderate (theoretical)

In vitro CYP modulation; limited human pharmacokinetic data. Monitor INR if added to anticoagulant therapy.

Panax ginseng + warfarin — Moderate

Reduced warfarin effect. Case reports of dropping INR. Avoid; monitor INR if used.

Panax ginseng + MAOIs (phenelzine) — Moderate to high

Headache, tremor, mania case reports. Avoid.

Maca + tamoxifen / hormone-sensitive cancers — Moderate (theoretical)

Theoretical estrogenicity (non-gelatinised form especially). Use gelatinised form; avoid in active hormone-sensitive cancer.

Should avoid

Side effects worth knowing

Ashwagandha — mild GI upset and drowsiness in 5–15% across pooled SR data. The serious signal is rare idiosyncratic hepatotoxicity (the NIH LiverTox database classifies the link as "likely") — stop on jaundice, dark urine, or right-upper-quadrant pain. Rhodiola — uncommon irritability, jitteriness, and insomnia, especially with evening dosing. Panax ginseng — uncommon insomnia, headache, and hypertension at higher doses. Maca — generally well-tolerated.

Practical upper bounds (no regulatory body has set ULs for any adaptogen — these are the highest doses tested in published human RCTs): ashwagandha 600 mg/d, rhodiola 680 mg/d, Panax ginseng 400 mg/d, maca 3,500 mg/d.

Conviction · Moderate

The category-level claim ("adaptogens as a unified class produce non-specific stress resistance in healthy adults") is not supported by the human RCT base. Per-plant per-endpoint per-population conviction is below.

  • Ashwagandha for stressed adults HIGH
  • Rhodiola for acute mental fatigue MODERATE
  • Panax ginseng for cognitive performance under stress MODERATE
  • Maca for menopausal symptoms (gelatinised) MODERATE
  • Adaptogens as a unified class LOW
  • "Healthy energy" / general stress immunity LOW–DEBUNKED
  • Mushroom adaptogen blends (lion's mane / reishi / cordyceps) EARLY
  • Eleuthero / Schisandra / Cordyceps for performance or longevity LOW
What would change this

A pre-registered, independent (non-industry-funded), double-blind, placebo-controlled multi-arm RCT of N≥400 healthy adults under documented chronic occupational stress (validated by hair cortisol baseline), randomised to standardised ashwagandha 600 mg/d, standardised rhodiola 400 mg/d, Panax ginseng 400 mg/d, a multi-adaptogen blend, and placebo, for 12 weeks or longer, with primary endpoints of validated PSS-10, salivary cortisol AUC, sleep architecture (PSG), and a pre-specified composite resilience outcome — showing the multi-adaptogen blend produces greater improvement than the best-performing single adaptogen with non-overlapping confidence intervals — would upgrade the category-level claim from LOW to MODERATE.

Worth Your Money?

Weekly cost£4–£7 per week for one standardised single-plant extract at trial dose. Multi-adaptogen "stress blends" run £6–£11 per week and almost always under-dose each component.
Worth it ifYou are documentably stressed, fatigued, or peri/postmenopausal AND you are buying a single standardised extract matched to your specific endpoint (ashwagandha for stress; rhodiola for acute mental fatigue; ginseng for cognitive load under stress; gelatinised maca for menopausal symptoms).
Lower priority ifYour sleep is under 7 hours, your protein is under 1.6 g/kg, you skip walks most days, or you are buying a five-herb "stress blend" expecting category synergy. Better first dollars: sleep, protein, walking, then a single standardised extract if the symptom remains.
Conditional Value

Go Deeper

Want to stop wasting money on supplements that don't work? The Verdict reviews one every week — free.

Subscribe Free
Claims vs Evidence — See What the Research Found

What People Claim

Adaptogen marketing claims visualization
"Adaptogens are herbs that help your body adapt to stress. Take this five-herb blend daily for non-specific stress resistance, natural energy, balanced cortisol, and immune normalisation. Backed by Soviet-era research and 5,000 years of Ayurvedic and Traditional Chinese Medicine tradition."

The category sits on three pillars in the marketing copy: (1) the 1947 Lazarev "adaptogen" concept and the 1969 Brekhman criteria, (2) traditional medicine lineage, and (3) the implication that the body intelligently routes the herbs to wherever they're needed. The marketing implies a single category mechanism across very different plants. It implies that more plants in one capsule equals more benefit. It implies that healthy people get "stress immunity" from daily use. None of those three implications is supported in the modern RCT base.

What the Evidence Actually Shows

Evidence by endpoint visualization

Per-endpoint, per-plant, per-population is how the evidence actually maps. Each row is a specific claim plus the evidence strength behind it.

ClaimPlantStrengthVerdict
Stress / anxiety in stressed adultsAshwagandhaSTRONGWorks
Cortisol modulation in stressed adultsAshwagandhaMODERATEWorks (modest)
Acute mental / physical fatigueRhodiola SHR-5MODERATEPromising (acute, short-term)
Cognitive performance under stressPanax ginsengMODERATEPromising
Menopausal symptom reliefMaca (gelatinised)MODERATEWorks (specific population)
Strength & recovery in trained menAshwagandhaMODERATEPromising — needs independent replication
"Stress immunity" in healthy unstressed adultsAny adaptogenWEAKUnproven
Multi-adaptogen blend synergy5+ herb stacksWEAKUnproven (no RCT)
Testosterone elevation in eugonadal menAshwagandha / macaWEAKUnproven (industry-funded story)
Mushroom adaptogen blendsLion's mane / reishi / cordycepsEMERGINGEarly signal (one 2026 RCT)
Eleuthero / schisandra / cordyceps for performance & longevityVariousWEAKUnproven

What would change the category claim: a pre-registered independent RCT showing a multi-adaptogen blend outperforms the best single plant for the same endpoint with non-overlapping confidence intervals. That trial does not yet exist.

The Full Picture — Mechanism, Debate & Nuance

How It Works

Adaptogen mechanism visualization

Each canonical adaptogen has its own pharmacology. There is no shared molecule, no shared receptor, no single pathway. What gets called "the adaptogen mechanism" is actually three different stories at three different evidence levels.

Layer 1 — HPA axis modulation (the strongest signal). Standardised ashwagandha extracts reduce salivary and serum cortisol in already-stressed adults. The mechanism is glucocorticoid receptor downregulation and 11β-HSD type 1 inhibition. Rhodiola shows a similar but smaller cortisol effect. This is real biology — but it is "modest cortisol smoothing in stressed adults," not "stress immunity."

Layer 2 — Plant-specific neuroendocrine action. Withanolides (ashwagandha) hit GABA-A and serotonin signalling. Rosavins and salidroside (rhodiola) influence monoamine turnover. Ginsenosides (Panax) modulate cholinergic and dopaminergic tone. Macamides (maca) act on the endocannabinoid system via FAAH inhibition — which is why maca helps menopausal symptoms but does nothing to testosterone. These are distinct mechanisms with distinct endpoints. The category umbrella obscures this.

Layer 3 — The "adaptogenic stress-protein response." Panossian's framework proposes that all adaptogens upregulate Hsp70, neuropeptide Y, FOXO3, and other stress-response proteins, conferring cellular stress resistance. Almost all of this is preclinical (rodent or in vitro). Some human transcriptomic data exist, but the leap from "Hsp70 goes up" to "you'll handle real-life stress better" is not yet supported by RCT outcomes. Treat this layer as mechanism hypothesis, not clinical evidence.

The Debate

Industry-funded vs. independent

Salve 2023, Wankhede 2015 (KSM-66 sponsor): Ashwagandha 600 mg significantly reduces stress and increases serum testosterone 14–17% in stressed or training men.
VS
Independent literature: Stress-reduction signal real; testosterone effect attenuated or absent in eugonadal unstressed men.

Stressed and training populations had suppressed baseline testosterone; cortisol-mediated HPG recovery is partly real. Sponsor-driven endpoint selection inflates headline-friendly claims for unstressed users who would not get the same lift.

Category claim vs. plant-specific reality

Panossian 2010: Adaptogens act via a shared stress-protein response (Hsp70, NPY, FOXO3) — a unified pathway.
VS
Modern RCT outcomes: Endpoint-specific responses do not pool across plants. Each plant's clinical effect is best explained by plant-specific actives.

The shared mechanism is preclinical. Each plant's measurable clinical effect is plant-specific. The category is a marketing wrapper around heterogeneous pharmacology — the unified-pathway story is the mechanism hypothesis, not the clinical reality.

Rhodiola: positive vs. inconclusive

SHR-5 standardised trials (Darbinyan 2000, recent crossover RCTs): Acute mental-fatigue improvement.
VS
Ishaque 2012 SR (10 RCTs): "Contradictory and inconclusive" across the broader pool.

Standardisation quality drives the disagreement. Trials of properly standardised SHR-5 extract show the acute fatigue signal; the broader pool dilutes it with non-standardised products and Rhodiola crenulata adulteration. Buy SHR-5 specifically.

Honest Limitations

Product quality is the silent variable

"Ashwagandha" or "rhodiola" on a label tells you almost nothing about what's in the capsule. Trial extracts (KSM-66, Sensoril, SHR-5) are standardised to a marker compound and a process. Off-trial Amazon products are not. Independent testing repeatedly finds large gaps between label claims and content. A real pharmacology meeting an underdosed or adulterated product looks like a null trial in someone's kitchen.

Population mismatch

The signal in the literature comes from stressed, fatigued, peri/postmenopausal, or training populations. Healthy unstressed adults take adaptogens daily expecting "more energy" or "stress immunity," and there is no RCT base for that use case. The mechanism does not work like a vitamin for a deficiency that does not exist.

Concept-vs-mechanism mismatch

"Adaptogen" is a 1947 pharmacology concept lifted into 2020s wellness marketing. The category implies a unitary mechanism that the evidence does not support. Each plant has plant-specific actives and plant-specific endpoints. Buying a "stress blend" of five adaptogens is buying a regulatory-friendly framing, not a clinically validated stack.

The Nuance

Adaptogen nuance and population stratification

Who benefits most (ranked by evidence): adults with documented chronic stress (ashwagandha, STRONG); students or workers under acute cognitive load (rhodiola SHR-5, MODERATE); peri/postmenopausal women with vasomotor symptoms (gelatinised maca, MODERATE); stressed adults wanting cognitive performance (Panax ginseng G115, MODERATE); recreationally trained men (ashwagandha for strength, MODERATE — pending independent replication).

What doesn't work: "Adaptogens normalise whatever is out of balance" is the 1969 Brekhman conceptual claim — not a modern RCT finding. "Adaptogen blends are stronger than any single plant" — no published RCT compares a blend to its best single component. "Ashwagandha boosts testosterone in healthy men" — true mainly in stressed or training populations, mostly in industry-funded trials. "Maca raises testosterone" — null across all RCTs; the benefit is endocannabinoid via macamides. "Adaptogens build long-term stress immunity in healthy adults" — no human RCT pool tests this endpoint.

Cost-effectiveness: Standardised single-plant extracts at trial-validated doses are worth the spend for matched populations and endpoints. Multi-adaptogen blends are usually a worse use of money than the same spend on one well-chosen single-plant extract. "Adaptogens for general energy" in healthy unstressed adults is a skip — save your money for sleep, protein, and walking infrastructure first.

Food alternatives: None — these are not food compounds. The best adjacent "food" lever for stress and cognition in healthy adults is fixing sleep, fixing protein, fixing daily movement.

Sources

  1. Tewari D et al. (2021). Plant Adaptogens — History and Future Perspectives. Nutrients. PMID 34445021. Conceptual lineage from Lazarev / Brekhman to modern pharmacology.
  2. Della Porta M et al. (2024). Effects of Ashwagandha on stress and anxiety: A systematic review and meta-analysis. Explore (NY). PMID 39348746. SR + MA of 12 RCTs.
  3. Lopresti AL et al. (2023). Effects of Withania somnifera on Cortisol Levels in Stressed Human Subjects. Nutrients. PMID 38140274. Cortisol-focused SR; positive in 7 of 9 included trials.
  4. Verma N et al. (2020). Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human ailments. J Ethnopharmacol. PMID 32201301. Safety + interactions canonical review.
  5. Salve J et al. (2023). A standardized Ashwagandha root extract alleviates stress, anxiety, and improves quality of life in healthy adults. Medicine. PMID 37832082. RCT, 8 weeks, 600 mg [industry-adjacent].
  6. Wankhede S et al. (2015). Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. J Int Soc Sports Nutr. PMID 26609282. RCT N=57, 8 weeks + RT [industry-funded].
  7. Ishaque S et al. (2012). Rhodiola rosea for physical and mental fatigue: a systematic review. BMC Complement Altern Med. PMID 22643043. SR of 10 RCTs.
  8. Hung SK, Perry R, Ernst E. (2011). Maca (Lepidium meyenii) for treatment of menopausal symptoms: A systematic review. Maturitas. PMID 21840656. SR of 4 RCTs.
  9. Lee Y et al. (2025). Effect of Hydroponically Grown Red Panax Ginseng on Perceived Stress Level, Emotional Processing, and Cognitive Functions in Moderately Stressed Adults. Nutrients. PMID 40289951. RCT.
  10. Mishra LC, Singh BB, Dagenais S. (2021). Pharmacological evaluation of Ashwagandha highlighting its healthcare claims, safety, and toxicity aspects. J Diet Suppl. PMID 32242751. Safety + toxicity review.

Action ROI

Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.

Action ROI score
52/100 Low ROI Trust grade C
No as a category or a blend. The money is better spent on one matched single-plant extract.
Time
Low
Money
Medium
Effort
Low
Risk
Medium
Why this score
Why it didn’t score higher
Best for
Lower ROI if
Minimum effective dose
There is no category dose. The effective move is a single standardized extract at its trial dose: ashwagandha 300 to 600mg/day (KSM-66 or Sensoril), or rhodiola 200 to 400mg/day (SHR-5). A blend has no validated effective dose.
Track this

Get the complete dosing protocol

Evidence-scored dosing, timing, forms, and who should skip it. One page, no fluff.

Get the protocol

Related free research

Supplements
Plant Sterols & Stanols — The Verdict
 Supplements
Exogenous Ketones — The Verdict
 Supplements
Serrapeptase — Does the Silkworm Enzyme Actually Work?

There are 424 more inside

Conviction-scored verdicts on supplements, nutrition, training, physio, and recovery.

Explore all Get weekly verdicts